These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 37823294)

  • 1. Therapeutic response of oral chronic graft-versus-host disease to topical corticosteroids according to the 2014 National Institutes of Health (USA) consensus criteria.
    Siripornkitti W; Pengpis N; Chanswangphuwana C; Prueksrisakul T
    Med Oral Patol Oral Cir Bucal; 2024 Mar; 29(2):e219-e226. PubMed ID: 37823294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical characteristics of oral chronic graft-versus-host disease according to the 2014 National Institutes of Health (USA) consensus criteria.
    Pengpis N; Prueksrisakul T; Chanswangphuwana C
    Med Oral Patol Oral Cir Bucal; 2023 Mar; 28(2):e167-e173. PubMed ID: 36173715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Term Utilization Patterns of Topical Therapy and Clinical Outcomes of Oral Chronic Graft-versus-Host Disease.
    Shazib MA; Muhlbauer J; Schweiker R; Li S; Cutler C; Treister N
    Biol Blood Marrow Transplant; 2020 Feb; 26(2):373-379. PubMed ID: 31585167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Chronic graft-versus-host-disease involving the oral mucosa: clinical presentation and treatment].
    Elad S; Levitt M; M Y S
    Refuat Hapeh Vehashinayim (1993); 2008 Nov; 25(4):19-27, 72. PubMed ID: 19263864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of National Institutes of Health global scoring system for chronic graft-versus-host disease (GVHD) according to overall and GVHD-specific survival.
    Moon JH; Sohn SK; Lambie A; Ellis L; Hamad N; Uhm J; Gupta V; Lipton JH; Messner HA; Kuruvilla J; Kim D
    Biol Blood Marrow Transplant; 2014 Apr; 20(4):556-63. PubMed ID: 24447907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical significance of subcategory and severity of chronic graft-versus-host disease evaluated by National Institutes of Health consensus criteria.
    Sato T; Ichinohe T; Kanda J; Yamashita K; Kondo T; Ishikawa T; Uchiyama T; Takaori-Kondo A
    Int J Hematol; 2011 Apr; 93(4):532-541. PubMed ID: 21465116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II study of belumosudil for chronic graft-versus-host disease in patients who failed at least one line of systemic therapy in China.
    Wang Y; Wu D; Zhang X; Li Y; He Y; Liu Q; Xuan L; Li Z; Qi K; Sun Y; Wang S; Mo W; Gao L; Hua Y; Wang Y; Zhang Y
    BMC Med; 2024 Mar; 22(1):142. PubMed ID: 38532458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Term Morbidity and Mortality in Children with Chronic Graft-versus-Host Disease Classified by National Institutes of Health Consensus Criteria after Allogeneic Hematopoietic Stem Cell Transplantation.
    Inagaki J; Moritake H; Nishikawa T; Hyakuna N; Okada M; Suenobu S; Nagai K; Honda Y; Shimomura M; Fukano R; Noguchi M; Kurauchi K; Tanioka S; Okamura J
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):1973-80. PubMed ID: 26234723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful treatment of dry eye in two patients with chronic graft-versus-host disease with systemic administration of FK506 and corticosteroids.
    Ogawa Y; Okamoto S; Kuwana M; Mori T; Watanabe R; Nakajima T; Yamada M; Mashima Y; Tsubota K; Oguchi Y
    Cornea; 2001 May; 20(4):430-4. PubMed ID: 11333336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of budesonide mouthwash on oral chronic graft versus host disease.
    Sari I; Altuntas F; Kocyigit I; Sisman Y; Eser B; Unal A; Fen T; Ferahbas A; Ozturk A; Unal A; Cetin M
    Am J Hematol; 2007 May; 82(5):349-56. PubMed ID: 17109390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence and Outcome of Atypical Manifestations of Chronic Graft-versus-Host Disease: Results From a Retrospective Single-Center Analysis.
    Doering J; Perl M; Weber D; Banas B; Schulz C; Hamer OW; Angstwurm K; Holler E; Herr W; Edinger M; Wolff D; Fante MA
    Transplant Cell Ther; 2023 Dec; 29(12):772.e1-772.e10. PubMed ID: 37777112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Value of Cutaneous Disease Severity Estimates on Survival Outcomes in Patients With Chronic Graft-vs-Host Disease.
    Baumrin E; Baker LX; Byrne M; Martin PJ; Flowers ME; Onstad L; El Jurdi N; Chen H; Beeghly-Fadiel A; Lee SJ; Tkaczyk ER
    JAMA Dermatol; 2023 Apr; 159(4):393-402. PubMed ID: 36884224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An Open-Label Phase II Randomized Trial of Topical Dexamethasone and Tacrolimus Solutions for the Treatment of Oral Chronic Graft-versus-Host Disease.
    Treister N; Li S; Kim H; Lerman M; Sultan A; Alyea EP; Armand P; Cutler C; Ho V; Koreth J; Antin JH; Soiffer R
    Biol Blood Marrow Transplant; 2016 Nov; 22(11):2084-2091. PubMed ID: 27590106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perspectives on oral chronic graft-versus-host disease from immunobiology to morbid diagnoses.
    Tollemar V; Garming Legert K; Sugars RV
    Front Immunol; 2023; 14():1151493. PubMed ID: 37449200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Multiparameter Prognostic Risk Score of Chronic Graft-versus-Host Disease Based on CXCL10 and Plasmacytoid Dendritic Cell Levels in the Peripheral Blood at 3 Months after Allogeneic Hematopoietic Stem Cell Transplantation.
    Chirumbolo G; Dicataldo M; Barone M; Storci G; De Matteis S; Laprovitera N; Sinigaglia B; Barbato F; Maffini E; Cavo M; Bonifazi F; Arpinati M
    Transplant Cell Ther; 2023 May; 29(5):302.e1-302.e8. PubMed ID: 36796518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Corticosteroid-Free Primary Treatment of Chronic Extensive Graft-versus-Host Disease Incorporating Rituximab.
    Solomon SR; Sizemore CA; Ridgeway M; Zhang X; Smith J; Brown S; Holland HK; Morris LE; Bashey A
    Biol Blood Marrow Transplant; 2015 Sep; 21(9):1576-82. PubMed ID: 25985915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IL6-receptor antibody tocilizumab as salvage therapy in severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: a retrospective analysis.
    Kattner AS; Holler E; Holler B; Klobuch S; Weber D; Martinovic D; Edinger M; Herr W; Wolff D
    Ann Hematol; 2020 Apr; 99(4):847-853. PubMed ID: 32086584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. National Institutes of Health chronic graft-versus-host disease staging in severely affected patients: organ and global scoring correlate with established indicators of disease severity and prognosis.
    Baird K; Steinberg SM; Grkovic L; Pulanic D; Cowen EW; Mitchell SA; Williams KM; Datiles MB; Bishop R; Bassim CW; Mays JW; Edwards D; Cole K; Avila DN; Taylor T; Urban A; Joe GO; Comis LE; Berger A; Stratton P; Zhang D; Shelhamer JH; Gea-Banacloche JC; Sportes C; Fowler DH; Gress RE; Pavletic SZ
    Biol Blood Marrow Transplant; 2013 Apr; 19(4):632-9. PubMed ID: 23340040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral symptom intensity, health-related quality of life, and correlative salivary cytokines in adult survivors of hematopoietic stem cell transplantation with oral chronic graft-versus-host disease.
    Fall-Dickson JM; Mitchell SA; Marden S; Ramsay ES; Guadagnini JP; Wu T; St John L; Pavletic SZ;
    Biol Blood Marrow Transplant; 2010 Jul; 16(7):948-956. PubMed ID: 20139026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of budesonide and dexamethasone for local treatment of oral chronic graft-versus-host disease.
    Park AR; La HO; Cho BS; Kim SJ; Lee BK; Rhie JY; Gwak HS
    Am J Health Syst Pharm; 2013 Aug; 70(16):1383-91. PubMed ID: 23903476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.